Integra LifeSciences (IART) Wells Fargo 21st Annual Healthcare Conference summary

Key performance indicators and execution

• Revenue performed at or above expectations in the first two quarters, driven by improved supply reliability and operational discipline.

• Focus remains on consistent execution, margin expansion, cash flow generation, and deleveraging.

• Progress in recapturing market share and advancing innovation, especially with PMAs and expanded indications in implant-based breast reconstruction.

• International markets are expected to gain momentum, with stabilization and mid- to high-single-digit growth anticipated by 2027.

• Commercial conversations are shifting from supply management to clinical engagement, boosting sales force confidence.

Competitive advantages and commercial strategy

• Deep, longstanding relationships with surgeons and economic stakeholders are a core strength.

• Clinically proven product lines and leading brands provide a strong market position.

• Enterprise contracting and unified commercial leadership across business lines are key opportunities.

• Focus on making operations easier for sales reps and customers globally.

Financial outlook and margin expansion

• Organic growth guidance for the year is 0.8%-3.3%, with execution consistency as the main driver.

• EBITDA margin expanded to 18.7% in Q2; full-year guidance implies a 100 basis point improvement, mainly from gross margin gains and OpEx efficiencies.

• Remediation plan includes relaunching SurgiMend in Q4 and bringing additional products back to market through 2027.

• Cost-saving initiatives are expected to deliver $25M-$30M in 2026 and an incremental $10M-$15M in 2027.